Frameshift Peptide Vaccine Construction for MSI-H Cancers

Microsatellite instability (MSI) arises when the DNA mismatch repair (MMR) system fails to correct replication errors in short repetitive sequences. The resulting frameshift mutations generate novel C-terminal peptide sequences—frameshift peptides (FSPs)—that are entirely absent from normal tissue yet displayed on the surface of MSI-high (MSI-H) tumor cells via MHC molecules. This tumor-restricted expression profile, combined with the shared nature of many frameshift mutations across independent MSI-H tumors, positions FSPs as uniquely attractive targets for off-the-shelf cancer vaccine design. Creative Biolabs offers a comprehensive preclinical development platform for FSP-based cancer vaccines, spanning shared neoantigen discovery, multi-epitope construct engineering, formulation optimization, and functional immunogenicity validation in relevant in vivo models of MSI-H malignancy.

Why FSPs Represent a Distinct Class of Shared Neoantigens

Tumor-Specific yet Universally Shared

Unlike patient-specific point mutations that require individualized manufacturing, the most frequent frameshift mutations in MSI-H cancers—such as those affecting TGFBR2, BAX, and ACVR2—recur across patients, tumor types, and even species. A panel of as few as 20 shared FSPs can theoretically cover over 90% of MSI-H colorectal, endometrial, and gastric carcinomas. This shared immunogenicity profile enables a semi-universal, off-the-shelf vaccine approach that dramatically simplifies preclinical development and reduces per-patient manufacturing complexity.

The FSP Advantage:
FSPs are not merely tumor-associated—they are truly tumor-specific. Because the frameshift-generated C-terminal sequence never exists in healthy cells, the risk of on-target off-tumor autoimmunity is minimal, a key differentiator from shared tumor-associated antigens like HER2 or MUC1.

Core Preclinical Challenges We Address:
Prioritizing shared FSPs with confirmed MHC presentation across common HLA alleles.
Overcoming immune tolerance to chronically expressed frameshift neoantigens in established tumors.
Designing multi-epitope constructs that coordinate CD4+ helper and CD8+ cytotoxic T cell responses.
Integrating FSP vaccines with immune checkpoint blockade in in vivo efficacy models.

How FSP Vaccines Differ from Conventional Neoantigen Approaches

Key Comparison	Patient-Specific Neoantigen Vaccines	FSP-Based Shared Neoantigen Vaccines
Antigen Sharing	Private mutations; unique to each patient.	Recurrent across patients; off-the-shelf feasible.
Manufacturing Timeline	Weeks per individual; requires fresh tumor biopsy.	Pre-manufactured construct pools; same-day administration.
Safety Profile	Variable; depends on predicted epitope specificity.	Tumor-exclusive expression; minimal off-target risk.
Immune Tolerance Risk	Low for clonal neoantigens; high for subclonal.	Addressed via adjuvant co-formulation and multi-epitope design.

End-to-End FSP Vaccine Development Service Packages

Our preclinical services are organized into six interconnected modules, each tailored to the unique biology of MSI-H tumors and frameshift neoantigens. All modules can be fully customized—from FSP panel composition to adjuvant selection—to match your tumor indication and research objectives.

Discovery

Shared FSP Identification & Prioritization

Systematic mining of MSI-H tumor genomics data to pinpoint recurrent, immunogenic frameshift peptides with broad patient coverage.

MSI Profiling: Microsatellite marker analysis and MMR status confirmation in tumor samples.
FSP Mining: Computational identification of recurrent frameshift mutations from whole-exome and targeted panel data.
Immunogenicity Ranking: HLA binding prediction across common alleles combined with published immunogenicity data.
Patient Coverage: Estimation of population-level coverage for the selected FSP panel.

Design

Multi-Epitope Construct Engineering

Rational design of poly-epitope vaccine constructs encoding multiple shared FSP sequences for broad T cell activation.

Poly-Epitope Architecture: Linker optimization and epitope ordering for balanced MHC-I/II presentation.
Platform Selection: Synthetic long peptide (SLP) pools, DNA plasmid, or mRNA vaccine formats.
Codon Optimization: Sequence engineering for maximum expression in the chosen delivery system.
Construct Validation: In vitro expression confirmation and antigenicity screening.

Formulation

Adjuvant Selection & Delivery Optimization

Formulating FSP constructs with immune-potentiating adjuvants and delivery systems to overcome pre-existing tolerance.

Adjuvant Screening: Evaluation of Toll-like receptor (TLR) agonists, STING agonists, and saponin-based adjuvants.
Delivery Vehicles: Lipid nanoparticle (LNP) encapsulation or emulsion-based depot systems.
Dose-Ranging: Systematic dose-response studies to define the minimum immunogenic dose.
Stability Testing: Formulation integrity under storage and administration conditions.

Immunogenicity

Cellular & Humoral Immune Response Evaluation

Multi-parameter assessment of vaccine-induced immunity using both cellular and humoral readouts.

ELISpot Assays: IFN-γ and IL-2 secretion profiling for FSP-specific T cell responses.
Intracellular Cytokine Staining: Multi-color flow cytometry for CD4+/CD8+ T cell polyfunctionality.
CTL Killing Assays: Antigen-specific cytotoxicity against MSI-H target cells in vitro.
Antibody Profiling: Evaluation of FSP-specific humoral responses by ELISA.

Combination

Combination Strategy with Checkpoint Blockade

Designing and evaluating FSP vaccine combinations with immune checkpoint inhibitors for synergistic antitumor activity.

Anti-PD-1/PD-L1 Combinations: Scheduling optimization for vaccine priming followed by checkpoint release.
TIL Analysis: Post-treatment quantification of CD8+ T cell infiltration in tumor tissue.
Synergy Assessment: Statistical evaluation of combination vs. monotherapy efficacy in in vivo models.
Biomarker Discovery: Correlation of MSI burden and MMR status with treatment response.

QC Data & Translational Documentation

Comprehensive quality control and data packages to support downstream translational and regulatory planning.

Peptide Quality: Purity, identity, and endotoxin testing for synthetic FSP batches.
Construct Verification: Sequence confirmation and expression validation for DNA/mRNA constructs.
Potency Assays: Established in vitro correlates for lot-to-lot consistency assessment.
Study Reports: GLP-compliant documentation of all preclinical immunogenicity and efficacy data.

Optimized Preclinical FSP Vaccine Development Workflow

Phase 1 — Shared FSP Identification & Immunogenicity Prioritization

We analyze MSI-H tumor sequencing datasets to identify recurrent frameshift mutations in microsatellite loci of cancer-associated genes. Each candidate FSP is scored for HLA binding affinity across common alleles, predicted immunogenicity, and patient coverage frequency. Published immunopeptidomics data is cross-referenced to confirm which FSPs are naturally processed and presented on tumor cell surfaces.

Phase 2 — Multi-Epitope Construct Design & Synthesis

Selected FSP sequences are engineered into optimized poly-epitope constructs with strategic linkers that preserve independent MHC-I and MHC-II epitope processing. Depending on the chosen delivery platform—synthetic long peptide (SLP) pools, DNA plasmid, or mRNA—we perform codon optimization, structural stability modeling, and small-scale synthesis for initial screening.

Phase 3 — Adjuvant Co-Formulation & Delivery Optimization

FSP constructs are formulated with selected adjuvant systems (TLR agonists, saponin-based adjuvants, or STING agonists) and delivery vehicles (LNPs, emulsions). We perform systematic dose-ranging and formulation stability studies to identify conditions that maximize dendritic cell uptake, antigen cross-presentation, and Th1-biased immune polarization.

Phase 4 — Preclinical Immunogenicity Validation

Vaccinated animals are evaluated for FSP-specific T cell responses using ELISpot (IFN-γ), intracellular cytokine staining, and cytotoxic T lymphocyte (CTL) killing assays. Antibody responses are quantified by ELISA. We assess both CD4+ helper and CD8+ cytotoxic T cell functionality to confirm balanced, polyfunctional immunity against the encoded FSP panel.

Phase 5 — Combination Efficacy & Translational Proof-of-Concept

FSP vaccine candidates are evaluated for antitumor efficacy in MMR-deficient syngeneic mouse models, both as monotherapy and in combination with anti-PD-1 or anti-PD-L1 checkpoint inhibitors. Endpoints include tumor growth inhibition, overall survival, tumor-infiltrating lymphocyte (TIL) density, and immune memory markers. Complete data packages are compiled for translational planning.

Enabling Technologies for High-Potency FSP Vaccines

Multi-Epitope Construct Optimization

Rational poly-epitope design with cleavable linker sequences ensuring each FSP is independently processed and presented. This approach coordinates CD4+ and CD8+ T cell activation, overcoming the MHC-II bias typical of simple peptide pools and generating balanced Th1-type immunity against multiple shared frameshift neoantigens.

MSI-H Model Platform

Access to validated MMR-deficient syngeneic mouse models that recapitulate the high mutational burden and immune-infiltrated tumor microenvironment of human MSI-H cancers. These models enable rigorous in vivo evaluation of FSP vaccine efficacy and checkpoint combination synergy under physiologically relevant conditions.

Adjuvant Synergy Screening

Systematic comparison of TLR agonists, STING agonists, and saponin-based adjuvants for their ability to break immune tolerance to chronically expressed frameshift neoantigens. Our screening platform identifies adjuvant-formulation combinations that maximize dendritic cell activation and promote durable memory T cell responses.

Why Choose Creative Biolabs?

Deep MSI Immunology Expertise

Our team brings focused experience in MMR-deficient tumor biology, understanding the unique immune microenvironment of MSI-H cancers and its implications for vaccine design.

Shared Neoantigen Focus

Unlike platforms built solely for patient-specific neoantigens, our FSP service is purpose-built for the identification, validation, and formulation of shared, off-the-shelf frameshift neoantigens.

Flexible Modular Design

From FSP panel composition to adjuvant selection and delivery platform, every component of the vaccine construct can be tailored to your specific tumor indication and preclinical endpoints.

Integrated Combination Studies

We offer built-in capacity to evaluate FSP vaccines alongside checkpoint blockade or other immunomodulators, delivering combination efficacy data essential for translational decision-making.

Research Insight: Efficacy of Personal vs. Shared Frameshift Neoantigen Vaccines

Key Findings from Peterson et al. (2020) Preclinical Evaluation

The therapeutic feasibility of FSP-based cancer vaccines is demonstrated through a direct preclinical comparison between customized Personal Cancer Vaccines (PCVs) and a generic off-the-shelf shared vaccine—termed Frameshift Antigen Shared Therapeutic (FAST).

RNA-Based Neoantigen Predictability: Frameshift peptides (FSPs) arising from transcriptional errors or mis-splicing in RNA production offer an abundant, highly predictable source of neoantigens. Using high-density FSP microarrays, immunogenic FSPs can be mapped rapidly, facilitating both quick PCV customization and shared antigen target selection.¹
Equivalent Anti-Tumor Efficacy: The shared BC-FAST vaccine—assembled from the most prevalent FSPs across subjects—exhibits similar therapeutic power to customized PCVs. When delivered as monotherapies or in tandem with checkpoint inhibitors (such as anti-PD-L1 and anti-CTLA-4), both options significantly restrict primary tumor growth and extend survival.¹
Independent Metastasis Suppression: FAST vaccines show outstanding capabilities in reducing spontaneous pulmonary metastases. Interestingly, FAST-driven control over metastases operates independently of primary tumor arrest, showing robust systemic immunity even in the presence of established primary tumors.¹
Robust and Polyfunctional Immune Response: Both vaccines successfully overcome self-tolerance to induce highly active T-cell responses. Re-stimulated lymphocytes display a favorable Th1-biased profile, with polyfunctional CD4+ and CD8+ T cells producing IFN-γ, TNF-α, IL-2, and cytotoxic Granzyme B.¹

Reduction of spontaneous lung metastasis induced by Fs vaccines.

Fig.1 PFs vaccines inhibit spontaneous lung metastasis.^{1, 2}

FAQs Regarding FSP-Based Cancer Vaccine Services

FSP-based vaccines are specifically designed for tumors with microsatellite instability-high (MSI-H) status, which results from deficient DNA mismatch repair (dMMR). This includes a significant proportion of colorectal, endometrial, gastric, and upper urinary tract carcinomas, as well as Lynch syndrome-associated tumors. Our service includes MSI status verification as part of the initial project evaluation.

Yes. While we offer a standard panel of shared FSPs with broad coverage across MSI-H cancers, we can customize the panel based on your target indication. Our bioinformatics team will mine indication-specific mutation frequency data to identify the most relevant and highest-coverage FSP combination for your tumor type, ensuring maximum patient population relevance.

We support three primary platforms: synthetic long peptide (SLP) pools, DNA plasmid vaccines, and mRNA-based formulations. Each platform has distinct advantages—SLPs offer straightforward manufacturing, DNA enables poly-epitope encoding in a single construct, and mRNA provides rapid, transient expression with lipid nanoparticle delivery. We help you select the optimal platform based on your preclinical objectives.

Our immunogenicity evaluation includes ELISpot assays for IFN-γ and IL-2 secretion, intracellular cytokine staining for CD4+/CD8+ T cell polyfunctionality, cytotoxic T lymphocyte (CTL) killing assays against MSI-H target cells, and FSP-specific antibody profiling by ELISA. Both cellular and humoral arms of the immune response are systematically assessed in vitro and in vivo.

Yes. Given the established responsiveness of MSI-H tumors to checkpoint blockade, combination evaluation is a core part of our service. We design studies using anti-PD-1 or anti-PD-L1 antibodies in MMR-deficient syngeneic models, evaluating scheduling (vaccine priming before or concurrent with checkpoint release), tumor growth inhibition, overall survival, and immune biomarkers such as TIL density and exhaustion marker expression.